Evolus ticker
WebMedytox Inc., Ten Percent Owner at Evolus (EOLS), has a 26.67% success rate when buying and selling stocks. Top Stocks. Top Analyst Stocks Top Smart Score Stocks Top Insiders Stocks. ... Medytox Inc., Ten Percent Owner at Evolus, holds 5.07M shares in Evolus (Ticker: EOLS). Most recently, Medytox Inc. Sold $2,187,511 shares of Evolus … WebStock analysis for Evolus Inc (EOLS:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Evolus ticker
Did you know?
WebApr 11, 2024 · View Evolus, Inc EOLS investment & stock information. Get the latest Evolus, Inc EOLS detailed stock quotes, stock data, Real-Time ECN, charts, stats and … WebHow much is Evolus stock worth today? ( NASDAQ: EOLS) Evolus currently has 56,246,570 outstanding shares. With Evolus stock trading at $9.28 per share, the total value of Evolus stock (market capitalization) is $521.97M. Evolus stock was originally listed at a price of $11.50 in Feb 8, 2024.
WebTicker: EOLS; CUSIP Number: 30052c107; Tip: Access positions for across all investors ... By clicking the button below, your credit card will be charged $28.00 USD (one time) and … WebEvolus, Inc. is a medical aesthetics company. The Company is focused on providing physicians and aesthetic procedures and treatments. It also focuses on offering the self-pay aesthetic market and its product candidate, PrabotulinumtoxinA (DWP-450), is an injectable 900 kilodalton, or kDa, botulinum toxin type designed to address the needs of the large …
Web2 days ago · Company Description. Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers … WebFeb 8, 2024 · Evolus has raised a total of $310.5M in funding over 3 rounds. Their latest funding was raised on Dec 14, 2024 from a Post-IPO Debt round. Evolus is registered under the ticker NASDAQ:EOLS . Their stock opened with $12.00 in its Feb 8, 2024 IPO. Evolus is funded by 2 investors. Pharmakon Advisors and Oxford Finance LLC are the …
WebJun 26, 2024 · For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, …
WebFeb 8, 2024 · Evolus has raised a total of $310.5M in funding over 3 rounds. Their latest funding was raised on Dec 14, 2024 from a Post-IPO Debt round. Evolus is registered … parker fcs divisionWebSelected key stats of Evolus, Inc. (EOLS) including 10 year stock price and latest news. Key stats provide selected financials for rapid company overview including revenues, marketcap, P/E ratio, debt and much more. time warner cable sound issuesWebFind the latest Evolus, Inc. (EOLS) stock quote, history, news and other vital information to help you with your stock trading and investing. parker feed store in parker coWeb2 days ago · Company Description. Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. parker fast \u0026 tite thermoplastic fittingsWebFeb 7, 2024 · The shares of Evolus' common stock have been approved for listing on The Nasdaq Global Market and are expected to begin trading under the ticker symbol … parker fasteners authorized distributorsWebEvolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. parker feierbach recipesWebJan 10, 2024 · The second unit is named Alphaeon1 LLC and will provide the company's stockholders a way to continue to hold about 8.7 million shares of Evolus Inc. that were previously held by Alphaeon. Alphaeon said the units will retain the same shareholder base that was in place prior to the split. time warner cable special offers